A Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-Effect in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2017
At a glance
- Drugs ASN 002 (Primary)
- Indications Lymphoma; Rheumatoid arthritis; Solid tumours
- Focus Adverse reactions
- Sponsors Asana BioSciences
- 23 Jan 2017 Status changed from recruiting to completed.
- 27 Sep 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016.
- 27 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2016.